- Home
- ORMP vs HUMAW Comparison
ORMP vs HUMAW Comparison
Compare ORMP & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORMP | HUMAW |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | 220 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ORMP | HUMAW |
|---|---|---|
| Price | $2.98 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 162.2K | 14.2K |
| Earning Date | 11-13-2025 | 03-21-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 838.25 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.82 | $1.18 |
| 52 Week High | $3.24 | $1.34 |
Technical Indicators
Market Signals| Indicator | ORMP | HUMAW |
|---|---|---|
| Relative Strength Index (RSI) | 57.67 | 39.58 |
| Support Level | $2.83 | $0.08 |
| Resistance Level | $3.24 | $0.13 |
| Average True Range (ATR) | 0.16 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 52.59 | 26.29 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.